A detailed history of China Universal Asset Management Co., Ltd. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 28,657 shares of XERS stock, worth $96,574. This represents 0.01% of its overall portfolio holdings.

Number of Shares
28,657
Previous 17,418 64.53%
Holding current value
$96,574
Previous $39,000 107.69%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.06 - $2.96 $23,152 - $33,267
11,239 Added 64.53%
28,657 $81,000
Q2 2024

Jul 19, 2024

SELL
$1.7 - $2.45 $15,466 - $22,290
-9,098 Reduced 34.31%
17,418 $39,000
Q1 2024

Apr 29, 2024

BUY
$2.04 - $3.22 $21,507 - $33,948
10,543 Added 66.01%
26,516 $59,000
Q4 2023

May 21, 2024

SELL
$1.47 - $2.36 $15,498 - $24,881
-10,543 Reduced 39.76%
15,973 $37,000
Q4 2023

Jan 23, 2024

BUY
$1.47 - $2.36 $18,275 - $29,339
12,432 Added 351.09%
15,973 $38,000
Q3 2023

May 21, 2024

BUY
$1.8 - $2.69 $3,135 - $4,685
1,742 Added 96.83%
3,541 $6,000
Q3 2023

Oct 30, 2023

BUY
$1.8 - $2.69 $3,135 - $4,685
1,742 Added 96.83%
3,541 $7,000
Q2 2023

May 21, 2024

SELL
$1.82 - $2.98 $78 - $128
-43 Reduced 2.33%
1,799 $4,000
Q2 2023

Jul 27, 2023

SELL
$1.82 - $2.98 $78 - $128
-43 Reduced 2.33%
1,799 $5,000
Q1 2023

May 21, 2024

BUY
$1.03 - $1.63 $474 - $751
461 Added 33.38%
1,842 $3,000
Q1 2023

Apr 27, 2023

BUY
$1.03 - $1.63 $474 - $751
461 Added 33.38%
1,842 $3,000
Q4 2022

May 21, 2024

SELL
$1.14 - $1.65 $28,653 - $41,472
-25,135 Reduced 94.79%
1,381 $1,000
Q4 2022

Jan 31, 2023

BUY
$1.14 - $1.65 $123 - $178
108 Added 8.48%
1,381 $2,000
Q3 2022

Oct 21, 2022

BUY
$1.37 - $1.93 $1,744 - $2,456
1,273 New
1,273 $2,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $458M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.